Skip to content

Study on the Intervention Effect on Patients with Metabolic Syndrome of Dampness Syndrome

Study on the Intervention Effect on Patients with Metabolic Syndrome of Dampness Syndrome

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006575
Enrollment
Unknown
Registered
2022-09-09
Start date
2022-09-16
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic syndrome

Interventions

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.18-70 years old. 2.Those who meet the typical diagnosis of dampness syndrome in the Diagnostic Standard of Dampness Syndrome of Traditional Chinese Medicine V2.0. 3.Those who meet the diagnosis of metabolic syndrome in the Chinese Guidelines for The Prevention and Treatment of Type 2 Diabetes (2017 Edition). 4.Those who volunteer to participate in the study of this subject and sign informed consent forms.

Exclusion criteria

Exclusion criteria: 1. Patients with secondary abnormal blood glucose, blood lipids and blood pressure caused by nephrotic syndrome, hypothyroidism, renal failure, liver disease, systemic lupus erythematosus, myeloma, glycogen accumulation, lipoatrophy, acute porphyria and polycystic ovary syndrome. 2. Patients with dysglycemia caused by drugs (phenothiazines, ß-blockers, adrenocortical steroids, etc.). 3. Patients with systolic blood pressure = 180mmHg or diastolic blood pressure = 110mmHg after treatment. 4. Patients whose fasting blood glucose is still = 11.1mmol/L after drug treatment. 5. Patients with total cholesterol = 6.22mmol/L (240mg/dL) or low density lipoprotein cholesterol = 4.92mmol/L (190mg/dL) or triglyceride = 3.39 mmol/L after oral drug treatment. 6. Patients with malignant tumor, severe heart disease, hematological disease, cerebrovascular accident, severe trauma or major operation. 7. Pregnant or lactating women or those who plan to become pregnant during the trial or whose spouse plans to conceive. 8. People with allergies, who may be allergic to this drug or are mentally ill. 9. Other patients who can't cooperate for a long time.

Design outcomes

Primary

MeasureTime frame
Quantity of metabolically abnormal components;Score of Dampness Syndrome Scale;

Secondary

MeasureTime frame
Fasting plasma glucose;High density lipoprotein cholesterol (HDL-C);Interleukin-6;Insulin resistance index;Low density lipoprotein cholesterol (LDL-C);HbA1c;Triglyceride (TG);C-reactive protein (CRP);Total cholesterol (TC);Blood pressure;Uric acid (UA);Body mass index (BMI);Tumor necrotic factor-a (TNF-a);Waist;

Countries

China

Contacts

Public ContactYang Zhimin

Guangdong Provincial Hospital of Chinese Medicine

yangyo@163.net13822296363

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026